Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Esai Co., Ltd.

Hisashi Shibata

Yorihisa Hoshino

Shuhei Miyazawa

Shigeki Hibi

Yoshinori Takahashi

Kogyoku Shin

Takashi Yamanaka

Kazuo Hirota

Motohiro Soejima

Tatsuya Yoshiuchi

Mitsuhiro Ino

Kouichi Kikuchi

Koichi Kikuchi

Tetsuya Hirakawa

Toshihiko Kaneko

Shigeru Souda

Norihiro Ueda

Seiichiro Nomoto

Naoyuki Shimomura

Katsuya Tagami

Makoto Okita

Manabu Murakami

Masatoshi Fujimoto

Tsuneo Wakabayashi

Kiyoshi Oketani

Hideaki Fujisaki

Shinya Abe

Mutsuko Ono

Takaaki Kameyama

Isao Yamatsu

Hiroyuki Yoshimura

Mitsuo Nagai

Masanori Mizuno

Takashi Mori

Mutsuko Tabata

Takayuki Hida

Masae Fujisawa

Seiichi Kobayashi

Yoshihiko Kotake

Osamu Asano

Hitoshi Harada

Taro Terauchi

Nobuyuki Yasuda

Kunitoshi Takeda

Kokichi Harada

Masahiro Yasuda

Kodo Shikata

Minako Hashizume

Akira Inomata

Yorohisa Hoshino

A compound represented by the following formula (I), or salt thereof exhibits excellent CRF receptor antagonism, and sufficient pharmacological activity, safety and pharmacokinetic properties as a drug. 

[object Object]

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula or a salt thereof. Wherein Rdenotes a hydrogen atom, a Calkyl group, a Calkoxy group and the like; Rdenotes a halogen atom, a cyano group, a nitro group, a Calkyl group, a Calkenyl group, Calkynyl group and the like; Rdenotes a Caromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may have a substituent; and X, Y and X are independent of each other and each denotes N or CR(wherein Rdenotes a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally halogenated Calkyl group and the like) and, in this case, at least two of X, Y and Z denote CR.

Imidazo[1,2-b]pyridazine compound

Compounds represented by the general formula: [wherein Rrepresents methoxy, ethyl, methylthio, etc., R, Rand Reach represent hydrogen, a halogen, etc., Rand Reach represent &#x2014;X&#x2014;X&#x2014;X(wherein Xrepresents a single bond or &#x2014;CO&#x2014;, Xrepresents a single bond, &#x2014;NR, etc. and Xand Reach represent hydrogen, Calkyl, etc.), and Ar represents phenyl, pyridyl, etc.], salts thereof and hydrates of the foregoing.

Pyrazolo[1,5-a]pyridines and medicines containing the same

A compound represented by the formula: [wherein Ris methoxy, methylthio, ethyl, etc.; Rand Rare each independently cyclopropylmethyl, (4-tetrahydropyranyl)methyl, etc.; and two of R, Rand Rare Calkoxy while the remaining one is methoxymethyl, etc.], a salt thereof, or a hydrate of the foregoing. This compound has excellent antagonism against corticotropin-releasing factor receptor.

7-phenylpyrazolopyridine compounds

Pyrazolo[1,5-a] pyridines and medicines containing the same

The present invention provides a medicament having a gentle but strong defecation-promoting action without causing diarrhea. That is, it provides a defecation-promoting agent comprising a compound having an adenosine Areceptor antagonism, preferably an adenosine Areceptor antagonism, or a salt thereof.

Medicinal compositions promoting bowel movement

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof,wherein Ris a hydrogen atom, etc.; Ris a hydrogen atom, etc.; M' represents a hydrogen atom, a halogen atom or a Calkyl group; R&#x2032; represents a hydrogen atom or a Calkyl group; and W&#x2032; represents a phenyl group, pyridyl group, thienyl group, or furyl group, each being optionally substituted; and a pharmacologically acceptable salt thereof or hydrates thereof.

Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof.Wherein A, B and D are the same as or different from each other and each represents a group represented by the formula &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each represents a Calkyl group etc.), &#x2014;NR&#x2014; (wherein Rrepresetns hydrogen etc.) etc.; E and G are the same as or different from each other and each represents a group represented by the formula &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each represents hydrogen etc.; and p represents an integer of 0, 1 or 2); J represents a carbon atom or nitrogen atom, each substituted with Calkyl group optionally substituted with a halogen atom, etc.; K and L are the same as or different from each other and each represents carbon atom or nitrogen atom; M means hydrogen, a halogen atom, an optionally substituted Calkyl group etc.; and the partial structuremeans a single or double bond.

Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof,wherein

Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are described.

Pyridine derivatives having anti-ulcerative activity

To provide a compound which exhibits a serotonin antagonism and an acetylcholine release accelerating activity at a well-balanced activity ratio. An aminobenzoic acid derivative represented by the general formula (I) or (II) or a pharmacologically acceptable salt thereof: ##STR1## �wherein R.sup.1 represents a group represented by the formula: ##STR2## {wherein A represents a group represented by formula --CH.sub.2 --X--CH.sub.2 -- (wherein X represents O, &gt;N--R.sup.6 or&gt;CHR.sup.7 (wherein R.sup.6 represents lower alkyl and R.sup.7 represents hydrogen or lower alkoxy)), etc.; D and E each represents a group represented by formula --(CH.sub.2).sub.3 --, etc., and R.sup.2 represents lower alkyl, etc.}; R.sup.9 represents alkynyl; R.sup.10 represents amino, etc-; R.sup.11 represents halogen; R.sup.12 and R.sup.13 each represent lower alkyl; a is an integer of 1 to 5; and b is an integer of 0 to 5!.

Aminobenzoic acid derivatives

Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are disclosed.

Growing community of inventors

Ushiku, Japan

Hisashi Shibata